Paul Lorigan
- Oncology top 0.1%
- Molecular Biology top 1%
- Pulmonary and Respiratory Medicine top 0.5%
- Immunology top 1%
- Epidemiology top 1%
- Co-authors
- James LarkinCaroline RobertAntoni RibasGeorgina V. LongJean‐Jacques GrobFiona BlackhallAna AranceOmid Hamid
- Topics
- Cancer Immunotherapy and Biomarkers (95 papers)Melanoma and MAPK Pathways (83 papers)CAR-T cell therapy research (80 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Paul Lorigan
321 papers receiving 12.5k citations
Hit Papers
Peers
Comparison fields: 5 of 147
- Oncology 9.6k
- Molecular Biology 4.7k
- Pulmonary and Respiratory Medicine 2.6k
- Immunology 2.5k
- Epidemiology 2.0k
Countries citing papers authored by Paul Lorigan
This map shows the geographic impact of Paul Lorigan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Lorigan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Lorigan more than expected).
Fields of papers citing papers by Paul Lorigan
This network shows the impact of papers produced by Paul Lorigan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Lorigan. The network helps show where Paul Lorigan may publish in the future.
Co-authorship network of co-authors of Paul Lorigan
This figure shows the co-authorship network connecting the top 25 collaborators of Paul Lorigan. A scholar is included among the top collaborators of Paul Lorigan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Lorigan. Paul Lorigan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 1 | |
| 5 | 3 | |
| 6 | 3 | |
| 7 | 11 | |
| 8 | 14 | |
| 9 | 5 | |
| 10 | 13 | |
| 11 | 22 | |
| 12 | 7 | |
| 13 | Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancerbreakdown → | 397 |
| 14 | 27 | |
| 15 | 1 | |
| 16 | 272 | |
| 17 | Safety and pharmacokinetics of first-line amg 479 (mab to igf1r) or amg 102 (mab to hgf/sf) with platinum-based chemotherapy in extensive-stage small cell lung cancer (sclc) | 6 |
| 18 | 192 | |
| 19 | Phase II study of ET-743 in advanced soft-tissue sarcoma (ASTS) in adult: A STBSG-EORTC trial | 9 |
| 20 | Total CD34 yield and CFU-GM as mobolisation and subsequent engraftment after high dose chemotherapy. | 64 |
About Paul Lorigan
Paul Lorigan is a scholar working on Oncology, Immunology and Molecular Biology, having authored 330 papers that have together received 12.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (95 papers), Melanoma and MAPK Pathways (83 papers) and CAR-T cell therapy research (80 papers). The work is most often cited by research in Oncology (9.6k citations), Immunology (2.5k citations) and Pulmonary and Respiratory Medicine (2.6k citations). Paul Lorigan has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include James Larkin, Caroline Robert, Antoni Ribas, Georgina V. Long, Jean‐Jacques Grob, Fiona Blackhall, Ana Arance, Omid Hamid, Mark R. Middleton and Matteo S. Carlino. Their work appears in journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.